Intra-Cellular Therapies stock is trading -17.3% below its average target price of $91.64 after marking a 10.0% during today's afternoon session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $65.0 to $120.0 per share.
Intra-Cellular Therapies's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 5.0%. The stock's short ratio is 3.16. Since 2.32% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 89.7%. In conclusion, we believe there is mixed market sentiment regarding Intra-Cellular Therapies.
Institutions Invested in Intra-Cellular Therapies
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | FMR, LLC | 11% | 11,194,613 | $848,439,729 |
| 2024-03-31 | Vanguard Group Inc | 9% | 9,225,981 | $699,237,108 |
| 2024-03-31 | Blackrock Inc. | 8% | 8,077,758 | $612,213,286 |
| 2024-03-31 | Wasatch Advisors LP | 4% | 3,854,747 | $292,151,278 |
| 2024-03-31 | Bellevue Group AG | 3% | 2,819,482 | $213,688,543 |
| 2024-03-31 | Avoro Capital Advisors LLC | 2% | 2,475,000 | $187,580,252 |
| 2024-03-31 | State Street Corporation | 2% | 2,240,695 | $169,822,276 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 2,065,298 | $156,528,937 |
| 2024-03-31 | Invesco Ltd. | 2% | 2,072,981 | $157,111,231 |
| 2024-03-31 | JP Morgan Chase & Company | 2% | 1,755,948 | $133,083,300 |
